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Abstract
BCR-ABL+acute lymphoblastic leukemia (ALL) in adults has a poor prognosis with allogeneic stem cell transplantation
(SCT) considered the best curative option for suitable patients. We here characterize the curative potential of BH3-mimetics
differentially targeting mitochondrial BCL2-family members using a combination therapy approach with dexamethasone
and tyrosine kinase inhibitors targeting BCR-ABL. In BCR-ABL+ALL BH3-mimetics act by redistribution of
mitochondrial activator BIM, which is strongly required for cytotoxicity of the BCL2-specific BH3-mimetic ABT-199,
tyrosine kinase inhibitors (TKIs) and dexamethasone. BIM expression is enhanced by dexamethasone and TKIs and both
synergize with ABT-199 in BCR-ABL+ALL. Triple combinations with ABT-199, dexamethasone and TKIs efficiently
attenuate leukemia progression both in tissue culture and in primary cell xenotransplantation models. Notably, the dasatinib-
containing combination led to treatment- and leukemia-free long-term survival in a BCR-ABL+mouse model. Finally,
response to BH3-mimetics can be predicted for individual patients in a clinically relevant setting. These data demonstrate
curative targeted and chemotherapy-free pharmacotherapy for BCR-ABL+ALL in a preclinical model. Clinical evaluation,
in particular for patients not suitable for allogeneic SCT, is warranted.
Introduction
Acute lymphoblastic leukemia (ALL) is a genetically het-
erogeneous disease with a 5-year survival of about 40% for
adults. Precursor B-ALL with the Philadelphia-translocation
t(9;22)(q34;q11) defines a very high-risk group [1–3] and
encodes the BCR-ABL oncoprotein with constitutive tyr-
osine kinase activity (BCR-ABL+ALL). Targeted therapy
of BCR-ABL+ALL with ABL-specific tyrosine kinase
inhibitors (TKI) such as imatinib and dasatinib combined
with induction and post-remission chemotherapy prolongs
remission but relapse rates remain high [4]. Therefore,
allogeneic hematopoietic stem cell transplantation (SCT)
remains the therapy with the highest curative potential.
However, SCT has high transplant-associated morbidity
and mortality and is limited to younger and suitable patients
[4–7]. Therefore, improvement of pharmacotherapy remains
of crucial importance to improve survival of BCR-ABL+
ALL patients.
Cellular apoptosis can be induced either by mitochon-
drial or death receptor signaling. Mitochondrial outer
membrane permeabilization (MOMP) is considered the
point of no return of mitochondrial apoptosis [8, 9]. MOMP
releases cytochrome C into the cytosol thereby activating
the apoptosome and downstream effector caspases. MOMP
is controlled in part by protein-protein interactions between
pro- and anti-apoptotic BCL2-family members interacting
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mostly via α-helical BH3 domains and BH3 domain binding
grooves. MOMP is induced by transfer of BH3-only pro-
teins BIM or BID from the anti-apoptotic factors such as
BCL2, BCLXL or MCL1 to apoptotic proteins BAX and
BAK. This shift is facilitated by sensitizers such as BAD,
BIK, NOXA or PUMA [8, 9].
BH3 mimetics that directly target the BH3 domain
binding grooves of anti-apoptotic BCL2 proteins have been
developed based on affinity screens and structure-based
modeling. For example, ABT-737 binds to BCL2, BCLXL
and BCLW whereas ABT-199 and WEHI-539 specifically
bind to BCL2 and BCLXL, respectively [10, 11]. Binding
of BH3-mimetics is thought to either release BH3-only
proteins and/or to prevent their binding to anti-apoptotic
BCL2 proteins leading to BAK/BAX oligomerization.
Recently, ABT-199 has been clinically approved as the first
BH3-mimetic for the treatment of chronic lymphocytic
leukemia [12, 13]. We already demonstrated efficacy of
ABT-737 in a xenograft BCR-ABL+ALL model [14].
Furthermore, MCL1 inhibitors have been developed [15]
and recently entered clinical trials.
We hypothesized that BCR-ABL+ALL may be amen-
able to targeted therapy with BH3-mimetic-containing
drug combinations. We therefore biochemically examined
induction of MOMP by BH3 mimetics in BCR-ABL+
ALL and further explored a targeted and potentially curative
chemotherapy-free combination therapy consisting of ABT-
199, dexamethasone, and dasatinib in vitro and in vivo.
Methods
Patient material
BM and PB samples were collected from newly diagnosed
BCR-ABL-positive and negative B-lineage ALL, and CML
respectively. For further information see Supplementary
Material.
Animal experiments
Leukemic BV173 cells (BV173-SLIEW) (1 × 106) or
patient derived xenograft (PDX) cells were adoptively
transplanted into recipient NSG (NOD.Cg-Prkdcscid
Il2rgtm1WjI/SzJ) mice intravenously. For in vivo treatment
and leukemic monitoring see Supplementary Materials.
Short-term BH3-mimetics response assay
Ficoll gradient-purified mononuclear cells from PB from
newly diagnosed B-lineage ALL, from healthy volunteers,
CML CD34+ cells, or BV173 or SUPB15 cells were cul-
tured at 1 × 106 cells/ml in the presence of increasing
concentrations of ABT-199 (0, 0.001, 0.01, 0.1, 1 µM) for
3 h followed by staining with 50 nM TMRE (tetra-
methylrhodamine ethyl ester) for 20 min at 37 °C. Sepa-
rately, cells were treated with the ionophore FCCP (5 µM)
(Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone)
as a positive control. MOMP of viable cells was determined
by flow cytometry.
Pre-treatment of PDX cells co-cultured on bone marrow
derived mesenchymal stem cells (MSCs) or of BV173 cells
with dexamethasone (100 or 50 nM) and dasatinib (50 or
0.5 nM) was performed for 48 h prior to TMRE assay.
Cell culture, cloning of lentiviral constructs, apoptosis
analysis, proliferation assays, immunoprecipitation, immu-
noblotting and statistical methods are described in detail
in Supplementary Materials.
Results
Induction of mitochondrial apoptosis in BCR-ABL
+ALL by BH3-mimetics
Since the specific BCL2 inhibitor ABT-199 is now
approved for CLL therapy [16], we first analyzed the
ABT-199 half-maximal inhibitory concentrations (IC50)
in several BCR-ABL-positive and -negative ALL cell
lines (Fig. S1A). The IC50s ranged from 0.002 to
2 µM demonstrating ABT-199 cytotoxicity in most ALL
cell lines.
We next quantified MOMP induction by BH3-mimetics
in viable cells using a short-term flow cytometry-based
assay. Mitochondria were stained with TMRE using mito-
chondrial bleaching by the uncoupling agent FCCP as a
positive control. ABT-199 and ABT-737 rapidly induced
a decrease in TMRE fluorescence preceding apoptotic
death in BCR-ABL+ cells in a dose-dependent manner
(Fig. 1a, S1B). In contrast to ABT-199 and ABT-737,
WEHI-539 induced less (BV173) or no (SUPB15) MOMP
and apoptosis in these cells. MOMP induction highly
correlated with cell viability with r > 0.905 and 0.997 in
BV173 and SUPB15 cells, respectively (Figs. S1C, S1D).
We then used this short-term assay to analyze ABT-199
cytotoxicity in normal peripheral blood mononuclear cells
(PBMNCs), mononuclear cells from newly diagnosed BCR-
ABL-positive and BCR-ABL-negative B-lineage ALL
patients as well as chronic phase CML CD34+ cells. Cells
were incubated with 1 µM ABT-199 for 3 h followed by
TMRE staining and flow-cytometric analysis of living
cells. Normal PBMNCs and CML CD34+ cells show
almost no MOMP induction (reduction of MFI to 95.4%
and 99.6% only, respectively), whereas ALL blasts exhib-
ited a marked reduction of TMRE fluorescence (Fig. 1b).
Interestingly, BCR-ABL+ primary ALL cells were more
M. Scherr et al.
resistant against ABT-199 than BCR-ABL-negative leu-
kemic blasts with MFI-reduction to 71.3% and 39.0%,
respectively (p= 0.04). We did not observe a significant
difference in ABT-199-mediated MOMP induction between
samples with the e1-a2 (p190 BCR-ABL, n= 3) and the
b2-a2/b3-a2 (p210 BCR-ABL, n= 3) isoforms. These
data indicate that BCR-ABL may interfere with ABT-199
cytotoxicity in primary ALL cells.
Since BH3-mimetics act by release of MOMP activators
[8, 9], we analyzed the protein expression of mitochondrial
BCL2-family members in ALL cells. Expression of both
anti- and pro-apoptotic BCL2 members was heterogeneous
with low BIM (BCL2L11) expression in all BCR-ABL+
ALL lines and patient material (Figs. S1E, S1F and S1G).
Next, we examined the binding and the redistribution
of MOMP activators induced by different BH3-mimetics.
In the absence of BH3-mimetics, BIM but not BID bound
to BCL2 and BCLXL in BV173 and SUPB15 cells (Fig. 1c,
S1H). In contrast, BIM was hardly detectable in MCL1
immunoprecipitates. ABT-199 displaced BIM from BCL2
in a time- and dose-dependent manner leading to induction
of apoptosis as shown by PARP cleavage (Fig. S1I).
In parallel, BIM/BCLXL and BIM/MCL1 complexes
were formed (Fig. 1c, S1J). Finally, the binding profile
of BH3-mimetics determined BIM redistribution to anti-
apoptotic BCL2 proteins: ABT-199, WEHI-539, and ABT-
737 released BIM from BCL2-only, BCLXL-only, and
BCL2 and BCLXL, respectively, leading to increased
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Fig. 1 Induction of mitochondrial apoptosis in BCR-ABL+ALL by
BH3-mimetics. a (Left) BV173 were treated with various concentra-
tions of ABT-199, ABT-737, and WEHI-539 for 3 h followed by
staining with TMRE to determine MOMP of viable cells by flow
cytometry. Treatment with the ionophore FCCP served as positive
control, and fluorescence of untreated cells was set as 100%. (Right) PI
staining to monitor cell viability was performed by flow cytometry
after additional 21 h. Values are expressed as means ± SD (n= 3).
b PB mononuclear cells from newly diagnosed BCR-ABL-negative
ALL (n= 13), BCR-ABL-positive ALL (n= 7), CML CD34+ cells
(n= 7) and PB mononuclear cells from healthy volunteers (n= 6)
were incubated with 1 µM ABT-199 for 3 h for MOMP induction
followed by TMRE staining and FACS analysis of viable cells.
p-value was calculated using Student’s t-test (*p < 0.05). c BV173
cells were treated with 100 nM ABT-199 for the indicated periods
of time. Cellular lysates were immunoprecipitated with anti-BCL2,
anti-BCLXL, and anti-MCL1 antibodies, respectively. Total cellular
lysates and immunoprecipitates were subjected to western blot analysis
using the indicated antibodies. Quantification of band intensities
was normalized to the amount of precipitated target protein. d BV173
cells were stably transduced with lentiviral constructs encoding
specific shRNA targeting BIM or a control sequence and treated
with various concentrations of ABT-199, dexamethasone, imatinib
or doxorubicin for 48 h. PI staining was performed to monitor cell
viability. Values are expressed as means ± SD (n= 3). p-values were
calculated using Student’s t-test (**p < 0.01, ***p < 0.001)
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BIM binding to non-targeted BCL2-family members
(Figs S1J, S1K).
Dexamethasone (DEX) and BCR-ABL-specific tyrosine
kinase inhibitors (TKIs) are important and crucial compo-
nents of current pharmacotherapy of BCR-ABL+ALL.
Since DEX and TKIs are known to enhance BIM expres-
sion in ALL cells, we proposed that these compounds might
be especially useful in combination with ABT-199 in BCR-
ABL+ALL. Accordingly, DEX induced BIM expression
in BV173 and SUPB15 cells (Fig. S1L), and TKIs reduced
BIM phosphorylation in addition to a slightly enhanced
BIM expression (Fig. S1M). Furthermore, expression of
BCLXL and MCL1 [17] were reduced in the presence
of TKIs in BV173 and SUPB15 cells (Fig. S1M) in line
with earlier reports.
To validate the functional role of BIM for cytotoxicity of
BH3-mimetics, DEX, and imatinib (IM), we transduced
BV173 cells with shBIM with a transduction rate of more
than 90% yielding a more than threefold reductions of
BIM expression (data not shown). BIM knockdown
diminished cytotoxicity of ABT-199, dexamethasone and
imatinib indicating that all three compounds heavily
depended on BIM expression (Fig. 1d). In contrast, dox-
orubicin acted BIM-independently (Fig. 1d). Furthermore,
anti-BID shRNAs had no effect on the cytotoxicity of
either drug (data not shown). Thus, the cytotoxicity of
ABT-199, DEX, and imatinib depends on BIM expression,
suggesting that these drugs act within signaling pathways
which converge on induction of mitochondrial apoptosis.
Cooperation of ABT-199 with DEX and imatinib
Since these data provide a rationale to combine DEX
and imatinib with ABT-199 in BCR-ABL+ALL, we
examined a potentially synergistic action of ABT-199,
dexamethasone, and imatinib by dose-effect combination
index (CI) analysis. In BV173 cells, ABT-199, dex-
amethasone, and imatinib exhibited dose-dependent cyto-
toxicity, and both compounds synergized with ABT-199
with CI values of 0.5 and 0.19 (values < 1 considered
synergistic), respectively, whereas the triple-agent therapy
synergized with CI= 0.15 (Fig. 2a). In addition, while both
imatinib and DEX showed a late onset of cytotoxicity
achieving its maximum after 96 h or later, the triple com-
bination showed high efficacy already after 48 h. These data
demonstrate not only synergy but also an additional kinetic
benefit of the triple combination over dexamethasone or
imatinib. In contrast to BV173 cells, SUPB15 cells are
resistant to TKIs [18]. In agreement with this, SUPB15 cells
were killed by ABT-199 and DEX but not imatinib when
applied as single agents (Fig. S2). However, imatinib
strongly synergized with ABT-199 and ABT-199/DEX in
these cells with CIs of 0.40 and 0.03, respectively (Fig. S2).
Given the robust in vitro synergism of ABT-199, DEX,
and TKIs, we analyzed drug combinations in vivo using a
murine NSG xenotransplantation model with luciferase-
transduced BV173 cells to allow monitoring of leukemic
growth by bioluminescent imaging [19]. BV173 cells
rapidly induced aggressive acute leukemia with a maximal
survival of about 35 days (Fig. 2b). Treatment was initiated
one week after transplantation and confirmed engraftment
(detection of about 15% GFP+ cells in spleens of trans-
planted mice (n= 3 mice, range 14–17%). Mice were
treated orally with vehicle alone (leukemia control), or with
a combination of dexamethasone and imatinib as double-
agent and triple-agent (ABT-199/DEX/IM) therapy. The
ABT-199/DEX/IM combination was superior to DEX/IM
double-agent therapy both in terms of tumor growth and
survival (median survival 48.5 and 42 days, respectively, p
< 0.001). However, none of the mice obtained a complete
remission as detected by bioluminescence, and all mice died
during therapy due to leukemic progression indicating the
limitation of this combination therapy.
Curative pharmacotherapy of BCR-ABL+ALL with
ABT-199, DEX, and DAS
Dasatinib is a dual ABL/SRC and second generation ABL
inhibitor [20] which may be more efficient than imatinib
when combined with ABT-199. Similar to imatinib, dasa-
tinib enhanced expression of BIM and reduced expression
of BCLXL and MCL1 (Fig. S3A). Furthermore, dasatinib-
associated cytotoxicity heavily depended on BIM (Fig. 3a)
suggesting that inhibition of SRC kinases by dasatinib may
also converge on the induction of mitochondrial apoptosis.
DAS acted synergistically with ABT-199 (CI= 0.62) and
DEX plus ABT-199 (CI= 0.15) (Fig. 3b). Moreover and
similar to the imatinib-containing triple combination, DAS/
DEX/ABT showed maximal efficacy already after 24 h and,
thus, substantially earlier than dasatinib and dexamethasone
as single agents.
As DAS showed strong in vitro response with ABT-199
and DEX, we next sought to determine the efficacy of triple-
agent therapy with DAS in vivo. ABT-199/DEX/DAS was
much more efficient than DAS/DEX or ABT-199/DAS
leading to a more rapid and long-lasting tumor reduction to
even undetectable levels (Fig. 3c). Treatment was dis-
continued after 6 weeks, and five out of seven ABT-199/
DEX/DAS-treated mice remained leukemia-free for the
whole observation period of more than 35 weeks. In con-
trast, all DAS/DEX- and DAS/ABT-199-treated mice
rapidly died within two weeks after the end of treatment due
to progression of leukemia.
These results show superiority of DAS as compared to
IM and imply that additional DAS targets beside BCR-ABL
may also enhance synergy with ABT-199 and DEX.
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Modification of combination therapy by pulsatile
application of ABT-199
ABT-199 quickly (within hours) interrupted the BCL2/
BIM-binding in a time- and dose-dependent manner
(Fig. 1c and S1I). In contrast, the cytotoxicity of DEX
and DAS required several days to enhance BIM expression
(Figs. S3 and S1L). Accordingly, the kinetics of drug-
induced cytotoxicity differed between ABT-199 on one
side and DEX and DAS on the other (Fig. S4A). Interest-
ingly, the triple-agent therapy combined the rapid onset
of cytotoxic effects (ABT-199) with increasing efficacy
over-time (DEX, DAS). We therefore hypothesized that
initial BIM-preloading of BCL2 before administration of
ABT-199 may provide a strategy to optimize combination
therapies. In experiments with either continuous or pulsatile
delayed addition of ABT-199 to DEX and DAS at
doses with either equal or quarter “area under the curve”
(AUC) amounts of ABT-199, the pulsatile therapy was
equally effective at reduced AUC in BV173 and SUPB15
cells (Fig. 4a). In vivo, the combination therapy with
continuous application of DEX/DAS and pulsatile therapy
with ABT-199 on only 1 of 5 days (Fig. 4b) (ABT-199
AUC= 0.2 as compared to continuous ABT-199 applica-
tion as shown in Fig. 3c) induced leukemia control even
after discontinuation of therapy. However, all mice relapsed
within 4 weeks after end of treatment as demonstrated by
in vivo bioluminescence (Fig. S4B). These findings suggest
that pulsatile ABT-199 therapy might be inferior in
achieving long-term remission.
Effects of ABT-199, DEX, and DAS on BCR-ABL+ALL
primografts
Having demonstrated the superiority of the ABT-199/DEX/
DAS triple combination therapy to dual combinations in
BV173 xenograft models we wanted to test the efficacy of
this therapy more generally in patient-derived xenografts.
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We therefore established four primograft models from
BCR-ABL+ALL patients with one of them (L4951)
transduced with luciferase to allow in vivo imaging of
leukemic growth. All but L4951 primograft cells could be
cultured ex vivo on human bone marrow-derived MSCs
[20] (Fig. S5A). In cultures of P564, R610 and L4967 cells
on MSCs with increasing concentrations of ABT-199,
DEX, and DAS for 48 h all three drugs reduced the number
of viable cells in a dose-dependent manner with the triple-
agent combination being most effective and killing almost
all leukemic cells. However, drug-cytotoxicity was quite
heterogeneous with ABT-199 most and less effective in
P564 and R610 cells, respectively (P564 46% and R610
91% viable cells at 1 µM ABT199). In contrast, DAS
cytotoxicity was highest in R610 cells and only mild in
P564 cells (R610 50% and P564 94% viable cells at 100 nM
dasatinib), whereas sensitivity of L4967 cells to all three
drugs was intermediate (Fig. 5a). Nevertheless, cytotoxicity
of the triple combination was synergistic in all three PDX-
models with CI of 0.13, 0.10, and 0.11 for P564, R610 and
L 4967 cells, respectively.
We next evaluated the effects of DEX and DAS treat-
ment on MOMP induction by ABT-199. BV173 cells and
cells from the three primografts were cultured in the pre-
sence or absence of DEX and DAS for 48 h before MOMP
induction by ABT-199 was measured in the short-term
TMRE-Assay (Fig. 5b). In all four models, pre-incubation
with DEX/DAS significantly enhanced ABT-199 induced
MOMP induction corresponding to the synergistic cyto-
toxicity of these three drugs.
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Finally, we transplanted P564, L4951, and L4967 cells
into NSG mice and monitored survival and leukemic
engraftment by either flow cytometric analysis of human
CD45+ cell kinetics in peripheral blood (P564 and L4967)
or in vivo imaging (L4951). Due to limited cell numbers
only two mice were transplanted with R610 cells (data not
shown). Similar to the ex vivo data survival of untreated
control mice was heterogeneous with all mice dying
between 80 (rapid course) and 200 days (long course)
(Fig. 5c). In contrast, all mice treated with the triple com-
bination ABT-199/DEX/DAS survived the treatment period
and beyond, and only two mice transplanted with P564 cells
died about 100 days after the end of therapy. Figure S5B
summarizes the survival data for all mice with rapid death
due to untreated leukemia including both R610 mice
demonstrating a significant survival benefit upon triple
combination treatment. Flow cytometric analysis revealed
clearance of human cells in all mice 4 weeks after start
of treatment (Fig. 5d, P564 and L4967 cells). Similarly,
no L4951 cells were detectable by in vivo imaging upon
ABT-199/DAS/DEX treatment up to 2 weeks after end of
treatment (Fig. S5C). In addition, blood smears were free
of ALL blasts after 6 weeks of triple therapy in the
P564 model (Fig. S5D). Taken together our data from
biologically different primograft models support the con-
cept of triple-agent therapy with ABT-199/DEX/DAS for
efficient leukemia control.
Discussion
We here show that a combination pharmacotherapy with
ABT-199, dexamethasone and dasatinib is very effective
and potentially curative in BCR-ABL+ALL. BH3-
mimetics such as ABT-199 specifically target the BH3-
binding groove in anti-apoptotic BCL2-family members
thereby interrupting BH3-only protein binding [8, 9], while
both steroids and TKIs enhance expression of mitochondrial
BIM. TKIs additionally reduce expression of BCLXL and
MCL1 [17]. Accordingly, we found synergistic cytotoxicity
between ABT-199 on one hand and dexamethasone and
TKI on the other in both cell line and BCR-ABL+ALL
primograft models (see cartoon in S6).
Dexamethasone and the TKIs imatinib and dasatinib are
important and crucial components of current pharma-
cotherapy for BCR-ABL+ALL. In our BV173 xenograft
model triple-agent therapies of ABT-199, dexamethasone,
and both TKIs were superior to double drug combinations
both in terms of tumor growth and survival. However,
dasatinib was much more effective than imatinib in com-
bination with ABT-199 and dexamethasone with about 70%
treatment free and MRD-negative long-term survival. In
contrast, none of the mice treated with dual combinations of
ABT-199/DAS or DEX/DAS became free of leukemia or
survived after the treatment period for more than 2 weeks.
Since these data indicated an unexpected curative potential
the triple therapy was analyzed in more detail using dif-
ferent patients-derived primografts. ABT-199, DAS, and
DEX act synergistically in all primografts tested in spite of
heterogeneity in terms of cytotoxic response to ABT-199,
dasatinib and/or dexamethasone alone. Furthermore, all
mice engrafted with three different primografts not only
survived the treatment period but became MRD-negative
under ABT-199/DAS/DEX therapy demonstrating more
generally the efficacy of this triple combination. Interest-
ingly, dual combination therapy with ABT-199 and
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sed as means ± SD (n= 3). p-values were calculated by Student’s t-
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Treatment started 1 week after tumor inoculation. Kaplan–Meier sur-
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Fig. 5 Effects of ABT-199, DEX, and DAS on BCR-ABL+ALL
primografts. a Patient-derived P564 (left), R610 (middle), and L4967
(right) cells were plated 24 h prior to drug treatment onto primary
MSCs. Co-cultures were treated with increasing concentrations of
ABT-199, DEX, and DAS alone or in combination with fixed ratios.
Fluorescence microscopic analysis of Calcein AM/PI/DAPI staining
was performed to determine apoptotic cell death. Quantification of
viable cells by counting viable and apoptotic cells in three repre-
sentative microscopic pictures per well in triplicates. Values are
expressed as means ± SD (n= 3). CI values were calculated using the
Chou Talalay method. P564 CI(ABT/DEX/DAS)= 0.126; R610 CI
(ABT/DEX/DAS)= 0.099. L4967 (CI/ABT/DEX/DAS)= 0.112. b
BV173 and patient-derived P564, R610 and L4967 cells (primografts
on MSCs) were pretreated with DEX and DAS for 48 h before ABT-
199 application for 3 h and mitochondrial staining with TMRE.
Decrease in TMRE MFI is expressed as means ± SD (n= 3) as com-
pared to untreated controls set 100%. p-values were calculated by
Student’s t-test (*p < 0.05; ***p < 0.001). c NSG recipients received
1 × 106 P564, L4967, and L4951 PDX cells intravenously and survival
of control and triple combination treated mice (ABT-199 (20 mg/kg),
DEX (1 mg/kg) and DAS (10 mg/kg) by oral gavaging 5 days per
week) is shown. d Tumor cell kinetics was monitored by human CD45
expression in peripheral blood cells (P564 and L4967). Note that all
control mice engrafted with L4967 cells died before the time of ana-
lysis at 4 weeks
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dasatinib has recently been described by Leonard et al.
[19]. However, data on MRD negativity or treatment-free
long-term survival have not been reported in that study.
Accordingly, we propose the triple combination of ABT-
199/DAS/DEX as potentially curative in several xenograft-
models without excluding that other combinations or even
dual therapies may be effective in individual models. Per-
sonalized approaches including quantification of MOMP
induction by individual BH3-mimetics (see below) may
help to optimize individual therapies in the future.
Dasatinib is a dual SRC/ABL TKI additionally targeting
the LYN tyrosine kinase [20]. Therefore, LYN inhibition
may contribute to the superiority of dasatinib as compared
to imatinib in our experiments with inhibition of LYN
providing an additional disturbance of survival signals
beside those mediated by BCR-ABL. The observation that
the cytotoxicity of both imatinib and dasatinib depends on
BIM expression suggests that the additional dasatinib tar-
gets beside BCR-ABL may also converge on induction of
mitochondrial apoptosis.
Our data also suggest a potential common mechanism
of resistance with regard to induction of mitochondrial
apoptosis for dexamethasone [21], BH3-mimetics, and
TKIs in the absence of kinase domain mutations [22]. We
demonstrate an uncoupling of BCR-ABL tyrosine kinase
inhibition by imatinib from the induction of mitochondrial
apoptosis in SUPB15 cells but synergism with and some
“restoration” of imatinib cytotoxicity by ABT-199. The
underlying molecular mechanism is currently unknown
but may include differential expression of BCL2 or
other anti-apoptotic proteins. Lesions in alternate proteins
including SRC, JAK2, STAT3, and others have been
proposed to explain treatment failure despite effective
inhibition of BCR-ABL kinase activity [22]. Since ABT-
199 cooperates with and reconstitutes imatinib cytotoxicity,
we add loss of oncogene addiction at the level of MOMP
induction as a potential mechanism of resistance. Along
this line, a common polymorphism lacking the BIM-BH3-
domain reduces therapeutic responses to both TKIs in
CML and EGFR-inhibition in NSCLC [23]. For BH3-
mimetics, mechanisms of resistance may include a shift
in the dependency to different anti-apoptotic proteins, e.g.,
from BCL2 to BCLXL or MCL1, or mutations in the
respective binding sites [24–26].
The different kinetics of cytotoxicity associated with
ABT-199 and dexamethasone/TKI suggest that pulsatile
ABT-199 therapy with reduced AUC as compared to con-
tinuous application may be particularly effective. Never-
theless, although pulsatile application of BH3-mimetics
may indeed improve efficacy of combination therapies
in vitro, in vivo imaging showed subclinical relapse of
BCR-ABL+ALL in all mice treated this way. This could
be in part due to the different application schedule, the
reduction of ABT-199 dosage and/or the drug metabolism.
However, it may still be worth to study modified time
and dose schedules since a pulsatile application possibly
reduces the frequency and severity of adverse effects. In
particular, it will be interesting to study pulsatile adminis-
tration of ABT-737/ABT-263 with regard to the induction
of thrombocytopenia (which prevented further clinical
development) in such settings.
In our luciferase transduced BV173 BCR-ABL+ xeno-
graft model we observed different clinical outcomes,
namely treatment failure (dual combinations or triple com-
bination of imatinib, ABT-199, dexamethasone), complete
remission with early relapse (dose-modified combination
with dasatinib, ABT-199, dexamethasone) or potential cure
(“full dosis” triple combination of dasatinib, ABT-199,
dexamethasone). These data suggest that rapid clearance of
leukemia is necessary but not sufficient for cure. Rather
high-dose treatment is required for long-lasting disease
control and cure in addition to rapid tumor reduction. Our
model therefore provides a useful tool to differentially study
the impact of drug modifications on different clinical out-
come parameters.
The induction of MOMP by BH3-mimetics can easily be
visualized and quantitated on a single cell level in viable
cells by flow cytometry using modified BH3 profiling
techniques. This rapid assay provides a simple tool to
measure cellular responses to various BH3-mimetics and
may become particularly important to individually select
the most effective BH3-mimetic, since MCL1 inhibitors
and other BH3-mimetics are under clinical evaluation
or may enter clinical use in the near future. For primary
ALL cells, rapid quantification of MOMP induction will
be especially beneficial since these cells are short-
lived ex vivo. Once individual BH3-mimetics for BCL2,
BCLXL, MCL1, BCLW, and/or BFL1 are clinically
approved, individualized therapies based on MOMP-
profiling should be feasible.
In primary leukemic cells, ABT-199 cytotoxicity is
reduced in BCR-ABL+ as compared to BCR-ABL-ALL
which may be due to reduced BIM expression. Here, we
demonstrate that this inhibition can be reversed by combi-
nation therapy with dexamethasone and dasatinib. Recent
evidence published by Mueschen and colleagues suggests
that B-cell receptor signals or substitutes of them (e.g.
provided by the BCR-ABL tyrosine kinase) have to be well
balanced in B-lineage ALL [27]. For example, PTEN
inhibitors, SYK activators and even fasting (via altered
leptin-receptor signaling) can inhibit expansion of ALL cell
populations indicating that the survival/apoptosis balance
can be disturbed by several means [27–31]. According
to our data, BH3-mimetics in combination with dex-
amethasone and dasatinib might be most suitable to induce
mitochondrial apoptosis in BCR-ABL+ALL pointing to
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induction of mitochondrial apoptosis as a privileged ther-
apeutic target in ALL cells.
In summary, our data provide rationally designed tar-
geted, chemotherapy-free and potentially curative combi-
nation therapy with BH3-mimetics for BCR-ABL+ALL.
Clinical trials are warranted and should include prospective
testing of MOMP induction by BH3-mimetics. Due to its
high anti-leukemic activity the chemotherapy-free and oral
regimen with ABT-199, dasatinib and dexamethasone may
be particularly useful for the large group of elderly patients
not suitable for allogeneic stem cell transplantation.
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